市場調査レポート

商品コード

1371922

骨髄移植市場の2030年までの予測：移植タイプ別、適応疾患別、エンドユーザー別、地域別の世界分析

Bone Marrow Transplant Market Forecasts to 2030 - Global Analysis By Transplant Type, Disease Indication, End User and By Geography

出版日: 2023年10月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 609,303円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 770,805円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 932,307円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,101,150円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の骨髄移植市場は2023年に106億5,000万米ドルを占め、2030年には153億9,000万米ドルに達すると予測され、予測期間中のCAGRは5.4％です。

長骨の内部には、骨髄と呼ばれる柔らかい血管組織があります。造血幹細胞と間葉系幹細胞の2種類があります。骨髄の主な機能は、造血、リンパ球産生、脂肪貯蔵です。さらに、白血病やリンパ腫などの特定のがんを患う人々に対するユニークな治療法として、骨髄移植（BMT）があります。一般的に骨髄に存在する幹細胞は、骨髄移植の際に除去され、ろ過された後、ドナー（患者）または別の個人に戻されます。

がん撲滅を目的とする任意団体である米国がん協会が2022年1月に提供したデータによると、非ホジキンリンパ腫（NHL）は米国で最も多いがんの一つであり、がん全体の約4％を占めています。

血液疾患の増加

白血病、リンパ腫、多発性骨髄腫のような血液疾患は、世界でより一般的になりつつあります。環境暴露、生活習慣の変化、高齢化などがすべて関与しています。さらに、診断学や早期発見技術が向上した結果、より多くの症例が早期に発見されるようになり、治療や治癒の可能性がある骨髄移植への関心が高まっています。また、標的療法や精密医療技術の発達により、移植の恩恵を受けられる患者の数も増加しており、これらの技術を移植と組み合わせることで治療成績を向上させることができます。

高額な移植費用

骨髄移植市場の主な障壁のひとつは、移植にかかる費用の高さです。移植前の評価、コンディショニング・レジメン、実際の移植、移植後のケア、長期フォローアップなど、すべて高額な処置です。多くの患者は、たとえヘルスケアシステムが高度に発達している地域であっても、これらの費用が治療の障壁となる可能性があります。さらに、保険が必ずしも全額を負担してくれるとは限らないため、患者は経済的な負担が大きくなります。

個別化医療の近代化

骨髄移植の分野は、ゲノムおよび分子プロファイリングによって推進される個別化医療によって大きな影響を受けています。その人の遺伝的・分子的プロファイルに基づき、移植戦略や移植後の治療をカスタマイズすることで、移植成績を向上させ、合併症を減らすことが可能です。さらにこの戦略は、移植の一般的な有効性を向上させながら、悪影響を軽減します。

ヘルスケアコストと経済的制約

骨髄移植が患者やヘルスケアシステムに与える大きな経済的負担は、骨髄移植市場にとっての主な脅威のひとつです。移植前の評価、コンディショニング・レジメン、実際の移植、移植後のケア、長期的なフォローアップなど、高い費用がかかるため、多くの患者が移植を受けない選択をする可能性があります。さらに、高額な医療費は保険制度を圧迫し、十分なサービスを受けていない人々が移植を受けられなくなる可能性もあります。

COVID-19の影響：

骨髄移植市場において、COVID-19パンデミックは大きな影響を与えました。世界のヘルスケアシステムはパンデミックの影響を受け、医療資源を節約し、感染しやすい患者の感染リスクを軽減するために、緊急でない移植手術の延期や中止が行われました。しかし、移植を受ける患者の免疫不全状態に対する懸念が高まるにつれ、厳格な感染管理対策と移植プロトコルの修正が必要となっています。

予測期間中、白血病分野が最大となる見込み

骨髄移植市場では、白血病が最大の市場シェアを占めています。骨髄移植の最も一般的でよく知られた原因の1つは白血病であり、白血球の異常増殖を特徴とします。急性リンパ芽球性白血病（ALL）、急性骨髄性白血病（AML）、慢性骨髄性白血病（CML）など、さまざまなタイプの白血病の有病率が高いため、移植サービスの需要が大幅に増加しています。さらに、移植方法、支持療法、標的療法の改善により、白血病患者の成功率も向上しており、これがこの市場の拡大にさらに拍車をかけています。

外来手術センター部門は予測期間中に最も高いCAGRが見込まれる

骨髄移植市場では、外来手術センター（ASC）分野が最も高いCAGRを維持しています。ASCは、一部の治療や低侵襲手術を含むさまざまな外来外科処置を提供しています。ASCの人気が高まっているのは、手頃な価格で実用的なヘルスケアを提供でき、入院期間が短く、感染リスクが低いためです。さらに、ASCは近年、整形外科、眼科、消化器内科、疼痛管理など、多くの専門分野を含む多様なサービスを提供しています。

最大のシェアを占める地域

北米地域が骨髄移植の最大市場シェアを占めています。この優位性は、強力な規制環境、確立されたヘルスケア・インフラ、骨髄移植を必要とする血液疾患の高い有病率、最先端の医療技術など、多くの要因によるものです。さらに北米は、広範な研究開発努力、多額のヘルスケア支出、ドナープールの大きさなどの恩恵を受けています。同地域の市場リーダーシップは、骨髄移植の利点に対する患者やヘルスケア提供者の意識の高まりにも助けられています。

CAGRが最も高い地域：

骨髄移植市場のCAGRが最も高いのは中東・北アフリカ（MENA）地域です。ヘルスケア投資の増加、ヘルスケアインフラの整備、骨髄移植のような最先端治療に対する人々の意識の高まりなどが、この成長を後押ししています。さらに、アラブ首長国連邦、サウジアラビア、カタールは、MENA諸国の中でも医療インフラを大幅に改善し、国民がより簡単に骨髄移植を受けられるようにした国です。移植サービスに対する需要の高まりは、この地域で血液疾患の有病率が増加している結果でもあり、市場の拡大に拍車をかけています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第9章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第10章企業プロファイル

Gamida Cell Ltd.
Mesoblast Ltd.
American Type Culture Collection（ATCC）Inc
Lonza Group Ltd.
FUJIFILM Cellular Dynamics, Inc.
ReachBio LLC.
Sanofi-Aventis LLC.
PromoCell GmbH
Abbott Laboratories Inc
The Emmes Company LLC
CORESTEM, Inc.
StemCell Technologies.
Hemacare Corporation
AllCells LLC.
Lifeline Cell Technology LLC
ReeLabs Pvt. Ltd.
Charles River Laboratories
Merck Millipore Corporation

図表

List of Tables

Table 1 Global Bone Marrow Transplant Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
Table 3 Global Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
Table 4 Global Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
Table 5 Global Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
Table 6 Global Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 7 Global Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
Table 8 Global Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 9 Global Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
Table 10 Global Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
Table 11 Global Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
Table 12 Global Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
Table 13 Global Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
Table 14 Global Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
Table 15 Global Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
Table 16 Global Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 17 Global Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
Table 18 Global Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
Table 19 Global Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
Table 20 Global Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 21 Global Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
Table 22 North America Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
Table 23 North America Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
Table 24 North America Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
Table 25 North America Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
Table 26 North America Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
Table 27 North America Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 28 North America Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
Table 29 North America Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 30 North America Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
Table 31 North America Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
Table 32 North America Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
Table 33 North America Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
Table 34 North America Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
Table 35 North America Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
Table 36 North America Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
Table 37 North America Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 38 North America Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
Table 39 North America Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
Table 40 North America Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
Table 41 North America Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 42 North America Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
Table 43 Europe Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
Table 44 Europe Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
Table 45 Europe Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
Table 46 Europe Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
Table 47 Europe Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
Table 48 Europe Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 49 Europe Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
Table 50 Europe Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 51 Europe Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
Table 52 Europe Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
Table 53 Europe Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
Table 54 Europe Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
Table 55 Europe Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
Table 56 Europe Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
Table 57 Europe Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
Table 58 Europe Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 59 Europe Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
Table 60 Europe Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
Table 61 Europe Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
Table 62 Europe Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 63 Europe Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
Table 64 Asia Pacific Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
Table 65 Asia Pacific Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
Table 66 Asia Pacific Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
Table 67 Asia Pacific Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
Table 68 Asia Pacific Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
Table 69 Asia Pacific Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 70 Asia Pacific Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
Table 71 Asia Pacific Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 72 Asia Pacific Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
Table 73 Asia Pacific Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
Table 74 Asia Pacific Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
Table 75 Asia Pacific Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
Table 76 Asia Pacific Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
Table 77 Asia Pacific Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
Table 78 Asia Pacific Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
Table 79 Asia Pacific Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 80 Asia Pacific Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
Table 81 Asia Pacific Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
Table 82 Asia Pacific Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
Table 83 Asia Pacific Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 84 Asia Pacific Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
Table 85 South America Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
Table 86 South America Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
Table 87 South America Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
Table 88 South America Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
Table 89 South America Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
Table 90 South America Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 91 South America Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
Table 92 South America Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 93 South America Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
Table 94 South America Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
Table 95 South America Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
Table 96 South America Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
Table 97 South America Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
Table 98 South America Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
Table 99 South America Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
Table 100 South America Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 101 South America Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
Table 102 South America Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
Table 103 South America Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
Table 104 South America Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 105 South America Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
Table 106 Middle East & Africa Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
Table 107 Middle East & Africa Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
Table 108 Middle East & Africa Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
Table 109 Middle East & Africa Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
Table 110 Middle East & Africa Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
Table 111 Middle East & Africa Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 112 Middle East & Africa Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
Table 113 Middle East & Africa Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
Table 114 Middle East & Africa Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
Table 115 Middle East & Africa Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
Table 116 Middle East & Africa Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
Table 117 Middle East & Africa Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
Table 118 Middle East & Africa Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
Table 119 Middle East & Africa Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
Table 120 Middle East & Africa Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
Table 121 Middle East & Africa Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 122 Middle East & Africa Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
Table 123 Middle East & Africa Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
Table 124 Middle East & Africa Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
Table 125 Middle East & Africa Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 126 Middle East & Africa Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC23979

According to Stratistics MRC, the Global Bone Marrow Transplant Market is accounted for $10.65 billion in 2023 and is expected to reach $15.39 billion by 2030 growing at a CAGR of 5.4% during the forecast period. In the interior of long bones, there is a soft vascular tissue called bone marrow. Hematopoietic and mesenchymal stem cells make up both types of stem cells. The main functions of bone marrow are hematopoiesis, lymphocyte production, and fat storage. Additionally, a unique form of treatment for people with certain cancers, such as leukemia, lymphoma, or other conditions, is bone marrow transplantation (BMT). Stem cells that are typically found in the bone marrow are removed during a bone marrow transplant, filtered, and then returned to the donor (patient) or to another individual.

According to data provided by the American Cancer Society, Inc., a voluntary health organization dedicated to eliminating cancer, in January 2022, Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the U.S., accounting for about 4% of all cancers.

Market Dynamics:

Driver:

Increasing incidence of haematological disorders

Hematological disorders like leukemia, lymphoma, and multiple myeloma are becoming more commonplace in the world. Environmental exposures, alterations in lifestyle, and an aging population all play a role. Furthermore, as a result of improvements in diagnostics and early detection techniques, more cases are now being discovered at an earlier stage, which has raised interest in bone marrow transplantation as a potential treatment or cure. The number of patients who can benefit from transplantation has also increased as a result of the development of targeted therapies and precision medicine techniques, which can be combined with transplants to improve outcomes.

Restraint:

High transplantation costs

The high price of the procedure is one of the main barriers to the market for bone marrow transplants. The evaluation prior to the transplant, the conditioning regimens, the actual transplant, the post-transplant care, and long-term follow-up are all expensive procedures. Many patients may find these costs to be a barrier to care, even in areas with highly developed healthcare systems. Additionally, insurance might not always pay the full cost, leaving patients with sizable financial burdens.

Opportunity:

Modernization of personalized medicine

The field of bone marrow transplantation is greatly impacted by personalized medicine, which is driven by genomic and molecular profiling. Based on a person's genetic and molecular profile, it is possible to improve transplant outcomes and lower complications by customizing transplant strategies and post-transplant therapies. Moreover, this strategy reduces negative effects while improving the general efficacy of transplantation.

Threat:

Healthcare costs and economic constraints

The significant financial burden it places on patients and healthcare systems is one of the main threats to the bone marrow transplant market. Many patients may choose not to undergo transplantation due to the high costs involved, including those of pre-transplant evaluation, conditioning regimens, the actual transplantation, post-transplant care, and long-term follow-up. Additionally, high medical expenses can also put a strain on insurance plans and prevent underserved populations from receiving transplants.

COVID-19 Impact:

On the market for bone marrow transplants, the COVID-19 pandemic had a sizable effect. Worldwide healthcare systems were affected by the pandemic, which included the postponement or cancellation of non-urgent transplant procedures in order to conserve healthcare resources and reduce infection risks for susceptible patients. However, as concerns about transplant recipients Immuno-compromised states increased, strict infection control measures and modifications to transplant protocols became necessary.

The Leukemia segment is expected to be the largest during the forecast period

In the bone marrow transplant market, leukemia holds the largest market share. One of the most common and well-known causes of bone marrow transplantation is leukemia, which is characterized by the abnormal proliferation of white blood cells. The high prevalence of different leukemia types, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), significantly increases the demand for transplantation services. Moreover, the success rates for leukemia patients have also improved thanks to improvements in transplant methods, supportive care, and targeted therapies, which have further fueled this market's expansion.

The Ambulatory Surgical Centers segment is expected to have the highest CAGR during the forecast period

The bone marrow transplant market's, Ambulatory Surgical Centers (ASCs) segment holds the highest CAGR. ASCs provide a variety of outpatient surgical procedures, including some medical treatments and minimally invasive surgeries. Their growing popularity is a result of their capacity to offer affordable and practical healthcare, shorter hospital stays, and lower infection risks. Additionally, ASCs have diversified their offerings in recent years to include a number of specialties, such as orthopedics, ophthalmology, gastroenterology, and pain management.

Region with largest share:

The North American region holds the largest market share for bone marrow transplants. This dominance can be attributed to a number of things, including a strong regulatory environment, an established healthcare infrastructure, a high prevalence of haematological disorders requiring bone marrow transplants, and cutting-edge medical technologies. Additionally, North America benefits from extensive research and development efforts, significant healthcare expenditures, and a sizable donor pool. The region's market leadership has also been aided by growing patient and healthcare provider awareness of the advantages of bone marrow transplantation.

Region with highest CAGR:

The market for bone marrow transplants has seen the highest CAGR in the Middle East and North Africa (MENA) region. Increased healthcare investments, a growing healthcare infrastructure, and rising public awareness of cutting-edge treatments like bone marrow transplants are a few of the factors driving this growth. Moreover, the United Arab Emirates, Saudi Arabia, and Qatar are among the MENA nations that have made significant improvements to their healthcare infrastructure, enabling their populations to access bone marrow transplantation more easily. The rising demand for transplantation services is also a result of the region's increasing prevalence of haematological disorders, which is fueling the market's expansion.

Key players in the market:

Some of the key players in Bone Marrow Transplant market include: Gamida Cell Ltd., Mesoblast Ltd., American Type Culture Collection (ATCC) Inc, Lonza Group Ltd., FUJIFILM Cellular Dynamics, Inc., ReachBio LLC., Sanofi-Aventis LLC., PromoCell GmbH, Abbott Laboratories Inc, The Emmes Company LLC, CORESTEM, Inc., StemCell Technologies., Hemacare Corporation, AllCells LLC., Lifeline Cell Technology LLC, ReeLabs Pvt. Ltd., Charles River Laboratories and Merck Millipore Corporation .

Key Developments:

In June 2023, Lonza, a trusted partner of the pharmaceutical, biotech, and nutrition industries, has entered into a ten-year Virtual Power Purchase Agreement with IGNIS. A VPPA represents a tailored and adaptable solution that caters to the needs of companies like Lonza, which operates in multiple sites. Unlike traditional power purchase agreements, VPPAs offer more flexibility and attract investments in the solar electricity production facilities as they are not linked to photovoltaic production facilities through physical grids.

In January 2023, FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics' iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.

In October 2020, Gamida Cell Ltd., a leading cellular and immune therapeutics company, and Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their existing strategic collaboration for omidubicel, Gamida Cell's advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of an allogeneic hematopoietic stem cell transplant.

Transplant Types Covered:

Autologous Bone Marrow Transplant
Allogeneic Bone marrow Transplant
Other Transplant Types

Disease Indications Covered:

Leukemia
Lymphoma
Myeloma
Thalassemia
Myelodysplastic Syndrome
Myeloproliferative Disorders
Aplastic Anemia
Solid Tumors
Sickle cell Anemia
Other Disease Indications

End Users Covered:

Hospitals
Multispecialty Clinics
Ambulatory Surgical Centers
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Bone Marrow Transplant Market, By Transplant Type

5.1 Introduction
5.2 Autologous Bone Marrow Transplant
5.3 Allogeneic Bone marrow Transplant
5.4 Other Transplant Types

6 Global Bone Marrow Transplant Market, By Disease Indication

6.1 Introduction
6.2 Leukemia
6.3 Lymphoma
6.4 Myeloma
6.5 Thalassemia
6.6 Myelodysplastic Syndrome
6.7 Myeloproliferative Disorders
6.8 Aplastic Anemia
6.9 Solid Tumors
6.10 Sickle cell Anemia
6.11 Other Disease Indications

7 Global Bone Marrow Transplant Market, By End User

7.1 Introduction
7.2 Hospitals
7.3 Multispecialty Clinics
7.4 Ambulatory Surgical Centers
7.5 Other End Users

8 Global Bone Marrow Transplant Market, By Geography

8.1 Introduction
8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling

10.1 Gamida Cell Ltd.
10.2 Mesoblast Ltd.
10.3 American Type Culture Collection (ATCC) Inc
10.4 Lonza Group Ltd.
10.5 FUJIFILM Cellular Dynamics, Inc.
10.6 ReachBio LLC.
10.7 Sanofi-Aventis LLC.
10.8 PromoCell GmbH
10.9 Abbott Laboratories Inc
10.10 The Emmes Company LLC
10.11 CORESTEM, Inc.
10.12 StemCell Technologies.
10.13 Hemacare Corporation
10.14 AllCells LLC.
10.15 Lifeline Cell Technology LLC
10.16 ReeLabs Pvt. Ltd.
10.17 Charles River Laboratories
10.18 Merck Millipore Corporation